High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated September 19, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary completion date: Jul 31, 2024 to Dec 31, 2024v5
  3. Eligibility criteria expanded, about 90 words
    • Study description expanded, about 8 words
    • Study title expanded, about 2 words
    v4
  4. Re-verified, no change to tracked fieldsv3
  5. Eligibility criteria shortened, about 13 wordsv2
  6. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
EGFR mutated NSCLC patiens with CNS metastases have poor prognosis. High-dose furmonertinib (160mg/day) have produced high CNS PFS and ORR in second-line for EGFR T790M mutated NSCLC. Whether EGFR mutated NSCLC with CNS metastases can benefit from first-line treatment of high-dose furmonertinib has not been reported. This study aims to investigate the efficacy and safety of high dose furmonertinib in first-line treatment of EGFR mutated NSCLC patiens.
Trial Details
NCT Number NCT05379803
Lead Sponsor Hunan Province Tumor Hospital
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov